Skip to content

Functional Lesion Assessment of Intermediate stenosis to guide Revascularisation

Functional Lesion Assessment of Intermediate stenosis to guide Revascularisation - FLAIR

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON38052
Enrollment
210
Registered
2014-03-31
Start date
2014-06-03
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease coronary narrowing

Interventions

iFR- versus FFR-guided decision making on revascularisation or deferral of coronary stenoses

Sponsors

Imperial College London
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Age>18 years of age 2. Willing to participate and able to understand, read, and sign the informed consent document before the planned procedure. 3. Eligible for coronary angiography and/or percutaneous coronary intervention 4. Coronary artery disease in one or more native major epicardial vessels or their branches by coronary angiogram with visually assessed de novo coronary stenosis in which the physiological severity of the lesion is in question (typically 40-70% diameter stenosis). 5. Stable angina or ACS (non-culprit vessels only and outside of primary intervention during acute STEMI)

Exclusion criteria

Exclusion criteria: 1. Previous CABG with patents grafts to the interrogated vessel 2. Left main stenosis 3. Tandem stenoses separated by more than 10mm that require separate pressure guide wire interrogation or PCI (not to be interrogated or treated as a single stenosis). 4. total coronary occlusions. 5. Restenotic lesions. 6. Haemodynamic instability at the time of intervention (heart rate

Design outcomes

Primary

MeasureTime frame
Major adverse cardiac events (MACE) rate in the oFR and FFR groups at 30 days, 1, 2, and 5 years.

Secondary

MeasureTime frame
1. Death (all cause) at 30 days, 1, 2, and 5 years. 2. Death (cardiovascular) at 30 days, 1, 2, and 5 years. 3. Myocardial infarction at 30 days, 1, 2, and 5 years. 4. Repeat revascularization by PCI or coronary artery bypass graft surgery (CABG) at 30 days, 1, 2, and 5 years. 5. Costs associated with iFR or FFR guidance. 6. Quality of Lide (QOL) of patients included in the iFR or FFR guidance groups 7. Cost savings of removing secondary inverigations, by assessing.treating non-culprit acute coronary syndrome (ACS) at the time of index presentation.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)